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ABSTRACT
Background: There exists a National Cancer Registry Programme (NCRP) aimed at collecting
cancer patient data at the hospital and population level. 33 population-based cancer registries
(PBCRs) and 100+ hospital-based registries (HBCRs) are present. Continuous training of
professionals and monitoring of data completeness are a requisite to ensure generation of reliable
databases. Advances in information technology allow for proper planning and development in all
active registries. However, due to lack of time and personnel, systematic filling in of data takes a
back-seat in India.
Objectives: To develop a cancer registry for Shirdi Sai Baba Cancer Hospital and Research
Centre.
Methods: After performing a background check on the availability of relevant data on official
government websites, a case report form for adult and paediatric patients was developed. It was
then validated by 6 field experts. Patients and/or patient parties were interviewed personally
after seeking informed consent and providing Participant Information sheets to sensitize the
answerer regarding the details of the project. Each interview was completed within 10-15
minutes depending upon the co-operation and comprehension exhibited. The information was
transferred from hard copies of Case Report Forms (CRFs) to an MS Excel file and analysed.
Data was visualized on Microsoft Power BI and a soft, easily usable copy of the CRF was coded
with DOT NET while the Microsoft SQL server served as a database.
Results: A computerized module of CRF was formulated. Various demographic parameters like
age, sex, co-morbidities, menstrual status, familial history, proximity to industry and social
history were evaluated. Average age was found to be 45.08 ± 19.63 years. Among n=100
patients, 48% were male and 52% were females (65% of them were in menopause). Out of
n=100 patients, 13% patients resided near industrial areas suggesting a possible correlation with
cancer incidence. 27 different types of cancer were exhibited and blood cancer (24%) had the
most occurrences. During diagnoses, 83% patients were confirmed microbiologically. Over 50%
patients were treated with chemotherapy and it was found that most blood cancer patients
received Cytarabine (15%) and Cyclophosphamide (11%) followed by Rituximab, LAsparaginase and Danorubicin.
Conclusion: It is inferred that there is a diverse spatial distribution of the primary sites of
cancers and their geographical locations indicating the diversity of footfall in the hospital.
Demographical factors seem to play a significant role in the development of cancer. This
reinforces the need for a registry for a hospital like Shirdi Sai Baba Cancer Hospital and
Research Centre to aid research and epidemiological assessments. It also aids therapeutic
decisions and points at drug utilization patterns useful for drug procurement.
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1. INTRODUCTION
1.1 Definition
Cancer registration is defined as the process of ongoing methodical collection of data on
occurrence and characteristics of reportable cancers that generates reliable data on incidence and
survival from cancer.
1.2 Epidemiology
GLOBOCAN (Global Cancer Incidence, Mortality and Prevalence) 2018 reports mention an
estimate of 18.1 million new cancer cases (17.0 million excluding non-melanoma skin cancer)
and 9.6 million cancer deaths (9.5 million excluding non-melanoma skin cancers) in 2018. Lung
cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause
of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer
(11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal
cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. (1)
In males, lung cancer takes the lead in terms of mortality followed by prostate and colorectal
cancer (for incidence), liver and stomach cancer (for mortality).
Among females, breast cancer ranks the highest, followed by colorectal and lung cancer (for
incidence), and vice versa (for mortality) and then cervical cancer which ranks fourth for both
incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer
death, however, significantly varies across countries and within each country depending on the
grade of economic development and related social and lifestyle factors. It is noteworthy that
high‐quality cancer registry data, the basis for planning and implementing evidence‐based cancer
control programs, are not available in the majority of low and middle‐income countries. The
incidence of the majority of cancers in different continents varies disproportionately.
Among men, prostate, lung, colorectal, liver, esophagus, Kaposi sarcoma, leukemia, stomach,
NHL are the major cancers in Africa whereas, in Asia, the majority comprises of the lung, lip,
and oral cavity, liver, stomach, colorectal and prostate cancers. Breast and cervical cancers are
the most frequently diagnosed cancers in Latin America and the Caribbean, Africa, and most of
Asia. However, the most common female cancers in Asia also include lung (China, North
Korea), liver (Lao People's Democratic Republic, Mongolia), and thyroid (South Korea). (1)
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Figure 1: Estimated number of incident cases in all cancers for all ages and both sexes,
worldwide (1)
1.3 WHO framework
A global monitoring framework on non-communicable diseases was accepted by the WHO. It
aims to give an account on cancer incidence and type as an indicator for the 2025 mortality
target. A foundation to implement cancer prevention and control was constituted as the Global
Action Plan for the Prevention and Control of Non-Communicable Diseases (NCD). A vital
component is the monitoring of NCDs and their determinants and evaluation of progress over
time at national, regional and global levels. (1)
Two complementary cancer observation mechanisms elicit essential statistics on deaths (by
cause); disease (cancer) registers on morbidity.
Due to inadequate health system infrastructure and/or resources, national vital statistics in many
of the low and middle-income countries are unavailable, incomplete or erroneous. It is necessary
to acknowledge that cancer registration is always viable and in contrast to other diseases, cancer
is relatively easy to monitor.
1.4 Burden of cancer
A rising burden of cancer is observed in countries of all financial levels. The incidence rate of
many cancers in the western has drastically reduced due to the recognition of predominant risk
factors, early detection, and improved health-care treatment. In contrast to this, risk factors that
are directly proportional to the occurrence of cancer are on the rise in Low-income countries
(LICs). Common risk factors include smoking, alcohol consumption, and other lifestyle habits. (2)
4

To enhance the reduction of an enormous burden of cancers, actions like tobacco control,
vaccination, and lifestyle modifications are implemented. Apt treatment and supportive care can
also promote to the decline in the burden of suffering. To enhance treatment modalities, an
integrated effort will be required not only from individual country governments but also from
international agencies, donors, civil society, and the private sector.
1.5 Registry in India
The launch of the NCRP in 1964 by the Indian Council of Medical Research (ICMR) in India
marked the beginning of cancer registration. Although the NCRP presently has 33 PBCRs and
100+ HBCRs, Indian cancer registries, mostly in urban areas, cover less than 15% of the
population. The upcoming registries, however, are still in the infant stage.
However, the current data of these registries are not very reliable due to many overwhelming
reasons. The cost benefits, etiological factors, environmental exposures, and geographical factors
could be studied more. Registries must provide ease of access to existing data on risk factors
including exposures to the environment, personal habits, familial links as well as treatment
details like palliative care, costs, and quality of life. We need new technologies to facilitate the
integration of this information. (3)

Figure 2: Risk factors of cancer
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1.6 Progression of Cancer Registries Internationally:
The most primitive registry can be traced back to 1926 in Hamburg. In 1941, a PBCR in
Connecticut was established with aims to promote an epidemiological and natural perspective.
The Danish registry was then set up in 1942. (4)
1.7 Progression of Cancer Registry in India:
In June 1963, the earliest cancer registry in Mumbai, India was developed as a unit of the Indian
Cancer Society. It targeted at obtaining essential statistics on cancer from a precisely distinct
urban population. Accessibility to cancer incidence data on a continuous basis started with the
initiation of PBCRs at Mumbai in 1964, Pune in 1973, Aurangabad in 1978, Ahmedabad and
Nagpur in 1980. (4) However, cancer registration in India began with a full thrust in 1982,
through the initiation of the NCRP by Indian Council of Medical Research (ICMR). PBCRs then
extended to Bangalore and Chennai; HBCRs were initiated in Chandigarh, Dibrugarh, and
Trivandrum. Further expansion of the NCRP occurred with the initiation of urban PBCRs at
Bhopal and Delhi in 1987; rural PBCRs at Barshi (Maharashtra) in 1987; and HBCRs at the main
hospital of PBCRs in Bangalore, Mumbai, and Chennai in 1986. (4)
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2. NEED FOR STUDY
Considering the progressing rise in cancer incidence, consequential increase in life expectancy
and the dearth of information on the magnitude and pattern of cancer in India, ICMR initiated a
national network of cancer registration called NCRP in 1980. It aims to generate diverse data on
the magnitude and pattern of the cancer problem, to create an epidemiological platform and to
promote human resource development in cancer registration. (5)
India is a leading country with respect to cancer incidence and mortality. A good surveillance
system in the form of cancer registries is important for planning and evaluating cancer-control
activities. An integrated, systematic and public health approach to cancer prevention and control
is an essential part of this type of system. Thus, the necessity of cancer registry is facilitated by
cancer burden in the community and the information is used to evaluate and assess the impact of
cancer control strategies and thereby conduct research.
Since HBCRs are hospital-based, they can collect discreetly better data related to patient
care in the hospital. (6) Assessment of patient care to evaluate therapy in clinical trials and
strategizing hospital facilities are the well-known uses of HBCRs. (5)
There exists a relationship between HBCR data uses to geographic and logistical factors. It
implied that elevating the amount of trained personnel, specialized cancer registry software and
maximizing completeness of data could potentially increase their worth as tools to improve
cancer care. (7)
HBCR data has also been employed to evaluate the urban-rural differences in cancer patterns.
HBCRs situated in Bangalore, Chennai, and Thiruvananthapuram collected data and the data in
urban and rural areas was divided by matching the pin codes of permanent addresses of the
patients. Variations between urban and rural areas were observed in the percentage of leading
sites of cancer as well as the proportion of advanced and localized cancer. (6)
2.1 Extrapolation of HBCR to PBCR:
Defining the population level, required personnel, the physical location of a registry, the
equipment, and office space required, finances, legal aspect, and confidentiality are important
prerequisites to developing a PBCR.
HBCR collects information from a particular hospital located in a particular area. Hence,
integrating data from many hospitals can be used to develop a PBCR.
To observe demographic and epidemiological variation, an illustrative cancer data can be
obtained by increasing the number of PBCRs with the help of HBCRs.
According to the newsletter of NCRP volume XXII no.1 November 2017, there exists an
aberrancy in the progression of data. The data analysis was yearly, which shifted to being
monthly after 2001 without any justification. (8) Hence, through our study, we aim to generate
more reliable data for the Indian population starting with a hospital.

7

2.2 Uses of Cancer registry (4)
The imperative benefits of having a cancer registry are in multitude and the following provide a
brief description.
2.2.1 Obtaining Incidence data
Calculation and reporting of incidence rates are one of the vital uses of cancer registries in India.
2006 data reports from the Mumbai registry showed that the crude all-cancer incidence rate per
1000 population was 96.2 for females and 72.9 for males. Time-trend incidence analysis from
1982 to 2006 from the Mumbai registry revealed an increased incidence of cancers of liver,
gallbladder, prostate, kidney, brain, lymphomas, leukaemia’s among males; and cancers
involving: gallbladder, breast, uterus, ovary, kidney, lymphomas, leukemias and multiple
myelomas among females.
The incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for 28 cancers
in each Indian state over 26 years from 1990 to 2016 were published in the journal Lancet
Oncology. All cancers added to 5.0% of the total DALYs and 8.3% of the total deaths in 2016 —
an escalation of 90.9% and 112.8%, respectively, from 1990 for incident cancer cases, there was
an increase from 548,000 in 1990 to 1,069,000 in 2016. The crude cancer incidence augmented
by 28.2%. However, the age-standardized incidence rate remained the same. (9)
2.2.2 Performing Research
Cancer registry provides an important database to generate a scientific hypothesis in statistical
studies. For example, cervical cancer was found to be the most common cancer among women
through the elucidation of data from many Indian cancer registries. This data brought into
consideration several risk factors associated with cervical cancer such as early marriage, early
age at first coitus, early age at first childbirth, low socioeconomic status and poor genital
hygiene. It is estimated that by 2020, India, will have about 218,500 (19% of all sites cancers)
incident head and neck cancer cases. (10)
2.2.3 Cancer control strategies
Cancer registries can initiate and execute many cancer control plans as stated by the WHO.
Evaluation of community needs, measurement of the level of services required and supply of
appropriate level of resources can be facilitated by a robust and methodical cancer registry
database.
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AIMS & OBJECTIVES
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3.0 AIMS:
To develop and evaluate a Cancer Registry for Shirdi Sai Baba Cancer Hospital and Research
Centre.
3.1 OBJECTIVES:
1. To provide an epidemiological database for research purposes.
2. To identify the patterns of treatment of all types of cancers and their risk factors including
proximity to industrial areas, and demographic parameters.

10
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4. REVIEW OF LITERATURE
Non-transmissible diseases are mainly responsible for a majority of deaths globally and cancer is
in the lead. Cancer acts as a barrier to increasing life expectancy globally. Mortality and
incidence rate of cancer is increased worldwide. The reason is quite complex but is found to be
related to aging, population growth, and fluctuations in occurrence and distribution of risk
factors among which mainly are related to socioeconomic development.
Cancer emerges as a major public health concern in India. Every year around 12.5 lakh new
cases are diagnosed and claim lives of about 6.8 lakh patients per year. According to WHO in
2015, cancer was the leading cause of death among individuals of age <70 years in 91 of 172
countries. The data related to death from cancer cases in India is projected to rise to 13.1 million
through the year 2030. The cancer burden would rise further due to demographic transitions, the
effects of tobacco use and other risk factors. As per the latest data of India from GLOBOCAN
2018, the frequency of lip and oral cavity cancer is high leading it to be a leading cause of death.
(1)

According to NICPR (National Institute of Cancer Prevention and Research), there is a death of
one woman every 8 minutes due to cervical cancer in India and for every two women diagnosed
with cancer of the breast, one dies of the same. In 2018, nearly 3,17,928 deaths were reported
due to tobacco (smoked and smokeless) use in both genders. A total of 7, 84,821 death cases
were reported in 2018; among them 4, 13,519 comprised of men and 3,71,302 women. In males
over 25% of deaths are due to oral cavity and lung cancer whereas in females 25% comprises of
cancer of the breast and oral cavity. (11) In men and women, 47.2% is covered by the top five
cancers of all cancers. The mortality rate due to cancer can be reduced if it is prevented,
screened, diagnosed and treated at an early stage.

Table 1: Top cancers in men and women
12

4.1 Cancer Registry in India
In India, cancer registry involves systematic data collection so as to have a reliable incidence rate
and mortality rate, to lay a foundation for scientific research. Research may be epidemiological,
clinical, basic or for cancer control. The cancer registries are registered under the NCRP.
PBCR is an active source for obtaining cancer data in India. The registry personnel collect the
data on standard pro-forma by visiting various sources. Once a PBCR is established, all the
probable sources of cancer cases are identified. The main sources from where data can be
obtained are tertiary care specialist cancer hospitals, private hospitals, government hospitals,
nursing homes, pathology laboratories, medical records, hospice and registries of birth and death
through a standard case report form. Since the data is obtained from multiple sources, it is
screened for duplication. Matching parameters like name, age, sex, ICD-O (International
Classification of Diseases for Oncology), and ICD (International Classification of Diseases) 9/10
codes constitutes screening. After the screening, quality control checks are carried out and then
subjected to analysis and reporting. The cancer cases are coded according to the ICD for
oncology. The variables involved in data collection involve demographic information, diagnostic
parameters, staging parameters, and treatment parameters. (10)
4.1.2 Challenges
Cancer registration is mostly restricted to urban areas. The possible reason could be a
skewed distribution of cancer hospitals or PBCRs predominant to urban areas. In rural areas,
only two PBCRs are currently working. Also, many cases in the private sector do not come under
surveillance. With <15% population coverage the cancer registries are represented unevenly and
cannot be representative of the entire country. India is still lacking PBCRs in larger states like
Uttar Pradesh, Bihar, Rajasthan, and Odisha. (12)
Within a stipulated period of time without causing any delay, cancer registries should
provide reliable data. However, the data collection process is time-consuming and there is a lag
phase between the date of diagnosis and entry into the registry. Furthermore, the data collection
requires trained registrars which entail inordinate costs. Regarding the validity of the source, the
mortality reporting in India isn't flawless. Also, hospitals don't co-operate all the time in the
registration process which affects the completeness of the data and hence overall quality. (10)
Data collection is either at diagnosis or at death. The cases need to be followed up for
estimating survival, outcomes, and quality of life of cancer patients. These parameters help in
determining the treatment and effectiveness of the overall cancer services in the long run. In
India, a few PBCRs have done survival studies. (13)
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4.2 Cancer Registry in the United States
In the United States, the Surveillance, Epidemiology, and End Results (SEER) Program of the
National Cancer Institute (NCI) collects and publishes data on cancer incidence and survival.
The Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population
Sciences (DCCPS) supports SEER. SRP functions in cancer surveillance as well as uses
analytical tools in generating reliable population-based statistics.
There is a delay of 28 months between the end of the diagnosis year and the time the cancers are
first reported to the NCI. (10) The data is released to the public in the spring of the following year.
The Joinpoint Trend analysis software is used to calculate The Annual Percent Change (APC)
estimates. The SEER Site Recode ICD-O-3/WHO 2008 Definition does the cancer coding.
4.3 Cancer Registry in Japan
The Japan government has selected 289 hospitals to promote high-quality cancer care
nationwide. These hospitals were referred to as Designated Cancer Care Hospitals (DCCHs). The
function of DCCHs includes the collection of information on cancer care, provision of training to
health care professionals, highly specialized care to patients and accomplishment of the
information necessities of patients. Each DCCH has its own hospital-based registry. Tumor
registrars who are trained by the National Cancer Centre are hired to manage the registry. The
quality of data is certified in three ways:
1. Well trained personnel,
2. Software that checks for consistency and
3. The National Cancer Centre staff who provides support.
HosCanR, standard software, is developed by the National Cancer Centre for the DCCHs to
register cancer information. It regulates the entry of data and submission with a check on
consistency and de-identification. When inconsistent data entry is detected, a warning or error is
issued, depending on the nature of the inconsistency. The annual data is submitted by DCCHs to
NCC after which the results are published. (14)
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4.4 Characteristics of various registries- (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)
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16

METHODOLOGY
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5. METHODOLOGY
5.1 Study Site: The study was conducted at Shirdi Sai Baba Cancer Hospital and Research
Centre.
5.2 Study design: Prospective observational study.
5.3 Study period: 6 months
5.4 Sample Size: 100 patients
5.5 Ethical Approval:
The protocol for this study was approved by the Institutional Ethical Committee of Kasturba
Hospital, Manipal. (IEC/ 510/2018)
5.6 Study criteria: The study group comprised of patients admitted in the Oncology wards who
met the following criteria during the study period:
5.6.1 Inclusion criteria:
Any patient irrespective of age and sex diagnosed with cancer.
5.6.2 Exclusion criteria:
Patients not willing to participate
5.7 Data source:
The study population broadly represents the South Indian population. All the necessary and
relevant data were obtained from the medical records and interviews of patients diagnosed with
Cancer.
5.8 Study materials
 Participant Information Sheet (PIS) - Used to provide necessary details (purpose,
benefits/risks, procedure) regarding the study.
 Informed Consent Form – An Informed consent form in Kannada or English was
obtained from each participant before study initiation.
 Case Report Form (CRF) - A form containing 8 items were used to assess the information
of the patients who had cancer. (Physician information, demographic information,
medical history, social history, occupational history, diagnostic parameters, treatment
parameters, and outcomes).
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5.9 Operation modality
The study was carried out in 6 main stages:
Stage 1: Designing prototype data collection form
Stage 2: Validation of the form
Stage 3: Data collection
Stage 4: Data entry
Stage 5: Evaluation & Analysis
Stage 6: Replication into a web-based module

STAGE 1: Designing a prototype cancer registry form.
Standard forms of registries from different countries were compared and evaluated:
- Alaska Cancer Registry form, (26)
-Nevada Central Cancer Registry Cancer Incidence Reporting Form, (29)
-New Hampshire State Cancer Registry Cancer Report Form, (30)
-Republic of South Africa Cancer Registration Form, (31)
-Virginia Cancer Registry Form, (32)
-NCDIR’s (National Centre for Disease Informatics & Research) NCRP Patient Information
Form
Following which, a standard prototype cancer registry form for KMC was designed keeping in
consideration, the NCDIR form criteria. The form consisted of 8 items as mentioned above.

STAGE 2: Validation of the form
The designed form was then validated to ensure its applicability, relevance, and accuracy.
Validation procedure followed is as follows:
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Designing
the
validation
form

Consulting
Experts

Discussing
Results

Calculating
I-CVI and
S-CVI

Figure 3: Flowchart depicting workflow of form validation
1. The validation form was designed using a 4-point ordinal scale to avoid ambivalence.
2. 6 experts in the field of oncology were consulted to validate the form and provide feedback.
3. The CRF was divided into 8 items: physician information, demographic information, medical
history, social history, occupational history, diagnostic parameters, treatment parameters, and
outcomes
4. I-CVI (Item Content Validity Index) and S-CVI (Scale Content Validity Index) were
calculated.
5. I-CVI= No. of experts in agreement ➗ total no. of questions
6. S-CVI =No. of questions valid➗ no. of total questions= 8➗8 = 1
7. Results are depicted in the table as follows-
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APPROPRIATENESS:
#1

#2

#3

#4

#5

#6

Number in
agreement

Item CVI

1

X

X

X

X

X

X

6

1

2

X

X

X

X

X

-

5

0.83

3

X

X

X

X

X

X

6

1

4

X

X

X

X

X

X

6

1

5

X

X

X

X

X

X

6

1

6

X

X

X

X

X

X

6

1

7

X

X

X

X

X

X

6

1

8

X

X

X

X

X

X

6

1

Experts

Item no.

Table 3: Calculation of CVI-Appropriateness of each item
RELEVANCE
#1

#2

#3

#4

#5

#6

Number in
agreement

Item CVI

1

X

X

X

X

X

X

6

1

2

X

X

X

X

X

-

5

0.83

Experts

Item no.
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3

X

X

X

X

X

X

6

1

4

X

X

X

X

X

X

6

1

5

X

X

X

X

X

X

6

1

6

X

X

X

X

X

X

6

1

7

X

X

X

X

X

X

6

1

8

X

X

X

X

X

X

6

1

Table 4: Calculation of CVI-Relevance of each item
APPLICABILITY- Table 5: Calculation of CVI-Applicability of each item
#1

#2

#3

#4

#5

#6

Number in
agreement

Item CVI

1

X

X

X

X

X

X

6

1

2

X

X

X

X

X

-

5

0.83

3

X

X

X

X

X

X

6

1

4

X

X

X

X

X

X

6

1

5

X

X

X

X

X

X

6

1

6

X

X

X

X

X

X

6

1

7

X

X

X

X

X

X

6

1

8

X

X

X

X

X

X

6

1

Experts

Item no.
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8. Since the indices exhibited a value of >0.78, the questions were deemed valid and the next
stage was continued with.

Figure 4: Definitions of Validity terms (33)
STAGE 3: Data collection
1. Data of 100 patients was collected using the designed form.
2. After the informed consent was taken, the participant informant sheet was given.
3. The patient and/or patient party was asked a set of questions regarding their demographics
and relevant histories like, social, medical, familial etc.
4. Data were simultaneously recorded on printed copies of CRFs (separate for adult and
paediatric patients).
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STAGE 4: Data entry
1. The collected data was checked for aberrancies and collated thereafter.
2. It was then entered into MS Excel and re-checked for duplications.
3. This provides a platform through which the demographics and follow-up of the patient can
be assessed.
STAGE 5: Evaluation & analysis
The data entered was analyzed based on the demographic information, the primary site of cancer,
risk factors like social history, familial history, and co-morbidities.
1.

The extent of the contribution of risk factors to blood cancer occurrence was elucidated

2.

Proximity to industrial area and type of industry was indicated as a risk factor for cancer
incidence

3.

Diagnostic parameters were assessed w.r.t most used

4.
5.

Treatment parameters: most used drug w.r.t each cancer was tallied
Address of each patient was visualized w.r.t primary site of cancer

STAGE 6: Translation into a computerized module.
1.
2.
3.
4.
5.
6.

To aid ease of access and input, a computerized method of data entry was discussed to
creation.
The adult and paediatric CRFs are adapted for online entry using the DOT NET (.net)
framework on the front end and Microsoft SQL Server as the backend database.
Each of the 6 items in the CRF was purposed to reduce time in filling.
Controlled access arrangements were made
Single-entry/ Multiple-entry data sets were identified.
Radio buttons and text boxes were inserted as required.
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Figure 5: Log-in Page of Manipal Cancer Registry

Figure 6: First screen after log-in--CRF filling screen
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Figure 7: Demographic Parameters and Medical history filling area

Figure 8: Social and Smoking History filling area

26

Figure 9: Completion screen of the first 3 items of CRF
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6.RESULTS
A prospective pilot study was conducted comprising of n=100 patients to evaluate the
demographic parameters, risk factors, distribution and treatment modalities pertaining to cancer
in Department of Medicine Oncology, Shirdi Sai Baba Cancer Hospital and Research Centre.
6.1 Demographic Overview

Male: 48 (48%)

Sex {n (%)}

Female: 52 (52%)
45.08 ± 19.63

Age in years (mean ± S.D.)
Pre-puberty: 5

Menstrual Status

Active: 13

Menopausal: 34

Co-morbidities {n (%)}

Present: 40 (40%)

Absent: 60 (60%)

Familial History of Cancer {n
(%)}
Social History {n (%)}
a) Alcohol Use
b) Smoking
c) Alcohol Use + Smoking +
Chews tobacco
d) Chews areca nut

Present: 15 (15%)

Absent:85 (85%)

Proximity to industry as risk
{n (%)}

Present: 13 (13%)

Absent: 87 (87%)

Exposure to chemicals {n (%)}

Present: 15 (15%)

Absent: 85 (85%)

a) 8 (39%)
b) 6 (28%)
c) 5 (23%)
d) 2 (10%)

Table 6: Demographic Overview
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6.1.1 Sex
Out of n=100 patients enrolled in the study, 48 (48%) were male and 52 (52%) were female. This
shows a majority of subjects in the study were female.

Sex Distribution

52%

48%

Male
Female

Figure 10: Sex Distribution
6.1.2 Age
Among the 100 patients, majority of the patients fell under the age group of 51-60 years (24%)
followed by age groups 61-70 years (20%), 41-50 years (19%), 31-40 years (10%, 11-20 years
(8%), 0-10 years (8%), 21-30 years (7%), 71-80 years (4%) and 81-90 years (1%).

Age (in years)
Figure 11: Eliciting ages of all patients

30

6.1.3 Menstrual Status
Out of 52 female patients, 34 (65%) were in menopause, 13 (25%) were active and 5 (10%) were
at pre-puberty stage.

Menstrual status

Active
Menopause
Prepuberty

Figure 12: Menstrual Status of Female patients

6.1.4 Co-morbidities
Among n=100 patients, 40 (40%) had presence of co-morbidities whereas 60 (60%) did not have
co-morbidities.

6.1.5 Familial History
Out of n=100 patients, 15 (15%) had a family history of cancer and 85 (85%) did not report any
relevant family history.
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6.1.6 Social History
Among n=100 patients, 8 (39%) were consuming alcohol, 6 (28%) were smokers, 5 (23%)
consumed alcohol, smoked and chewed tobacco and 2 (10%) chewed areca nut historically.

Social history in Males
Alcoholic

10%
Smoker

39%

23%
28%

Alcoholic+Smoker
+Chews tobacco
Chews Areca nut

Figure 13: Social history in male cancer patients
6.1.7 Residence Near Industrial Area
Out of n=100 patients, 13 (13%) resided near an industrial area whereas 87 (87%) did not reside
near industrial area

Proximity to Industry

Yes
No

Figure 14: Proximity to industry
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6.1.7 (a) Association of cancer with residence near different types of industries and
duration of residency
It was inferred that patients with different malignant diagnoses resided near various industries,
viz., steel factory, nuclear power plant, steel factory, sugar factory, gear factory, popcorn factory,
garment factory, rice mill and cashew nut factory. Out of 13, 6 patients reported duration of
residence as:
Type of Industry

Duration of residence
(in years)

Stainless steel factory

60

Popcorn factory

50

Nuclear Power Plant

35

Mechanical factory

14

Garment Factory

7

Rice Mill

1

Table 7: Eliciting duration of residence near a particular industry

Figure 15: Quantifying number of patients to particular industry
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6.1.8 Exposure to Chemicals/ Pesticides/ Metals
Among n=100 patients, 15 (15%) were directly or indirectly exposed to either chemicals,
pesticides or metals and 85 (85%) were not in contact or exposed to any of the above.

Exposure to chemicals/pesticides/metals

15%
Yes
No
85%

Figure 16: Occupational/ Residential exposure to chemicals

6.2 Diagnostic Overview
Among n=100 patients, diagnoses were assessed and staged accordingly.
Diagnostic measures

Microbiology: 83%

Radiography: 35%

Clinical assessment:
3%

Status of disease at
diagnosis

Unstaged: 67%

Staged: 17%

Metastasized: 17%

Table 8: Diagnostic Overview
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6.2.1 Diagnostic Confirmation
Amongst n=100 patients, various diagnostic tests were carried out to identify the stage and
primary site of cancers; 69 (69%) were microbiologically confirmed i.e. cytology, histology tests
etc. 29 (29%) were confirmed by radiography and 2 (2%) were clinically evaluated and
confirmed.

Diagnostic confirmation
2%
29%

MICROBIOLOGY
RADIOGRAPHY
CLINICAL

Figure 17: Diagnostic Confirmatory tests performed
6.2.2 Status of Disease at Diagnosis
The n=100 patients were evaluated for staging and it was found that majority of cancer patients
61 (61%) were unstaged, 24 (24%) were staged and 15 (15%) were found to have metastasized.

Status of Disease

15%
Unstaged

24%

Staged

61%

Metastasized

Figure 18: Status of disease at diagnosis
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6.3 Treatment Modalities’ Overview
Various treatment modalities were adopted for managing cancer patients like chemotherapy,
radiation therapy, surgery and palliative care.
1st course of
treatment

More than 50% patients were given Chemotherapy

Average number of
cycles completed

4.11 amongst 52 patients

Palliative Care
Assessment

Most used antacid: Pantoprazole
Most used analgesic: Paracetamol
Most used anti-emetic: Ondansetron
Table 9: Treatment Modalities’ Overview

6.3.1 Treatment Pattern
Out of n=100 patients, 55 (55%) received chemotherapy, 34 (34%) underwent surgery, 9 (9%)
received radiation therapy and 8 (8%) did not receive any treatment at first.

Type of Treatment Received
First

Treatment Pattern
No treatment

8

Surgery

34

Radiation therapy

9

Chemotherapy

55
0

10

20

30

40

50

60

Number of Patients
Figure 19: Treatment Pattern in cancer patients

6.3.1 (a) Average Number of Cycles Completed
Out of the 55 patients who received chemotherapy, 4.11 was found to be the average number of
cycles that were completed for all patients.
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6.3.1 (b) Treatment modalities for Blood Cancer
Among n=100 patients, 24 (24%) were diagnosed with blood cancer and while assessing their
treatment strategies, it was found that most patients received Cytarabine (15.22%) and
Cyclophosphamide (10.87%) followed by Rituximab (8.7%), L-Asparaginase (8.7%) and
Danorubicin (8.7%).

Figure 20: Treatment modalities in blood cancer patients

6.3.2 Palliative Care Assessment
Supportively, care was provided to manage symptoms like pain, nausea, vomiting and to prevent
acidity.

6.3.2 (a) Management of pain
Out of n=100 patients, 1 (1%) received nalbuphine, 3 (3%) received morphine, 8 (8%) received
tramadol, and majority 25 (25%) received paracetamol to relieve pain.

37

Analgesic Consumption (Opioid & Non-Opioid)
30

Number of Patients

25
25
20
15
8

10
5

3

1

0
Nalbuphine

Morphine

Tramadol

Paracetamol

Drug names
Figure 21: Eliciting analgesic consumption
6.3.2 (b) Management of nausea & vomiting
Out of n=100 patients, 3 (3%) received palonosetron, 5 (5%) received domperidone and 12
(12%) received ondansetron.

Anti-Emetic Consumption
14
12

Number of Patients

12
10
8
6
4

5
3

2
0
Palonosetron

Domperidone

Ondansetron

Drug names
Figure 22: Eliciting anti-emetic consumption
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6.3.2 (c) Management of acidity
Out of n=100 patients, 59 (59%) received Pantoprazole whereas 6 (6%) received Ranitidine to
reduce gastric acid secretion.

H2 Antagonist & PPI Consumption
70
59

Number of Patients

60
50
40
30
20
6

10
0

Ranitidine

Pantoprazole
Drug Names

Figure 23: Eliciting H2 antagonist and PPI consumption
6.4 Overview of Cancer Distribution
Amongst n=100, primary sites of cancer were identified as bladder (2), blood (24), bone
(3), brain (4), breast (12), buccal mucosa (4), cervix (4), endometrium, kidney (3), larynx (1),
lungs (4), lymph (2), ovary (10), plasma (5), testis (3), stomach (4), tongue (3) and each of
trachea, rectum, placenta, parotid, lymph node, large intestine, intestine, esophagus,
endometrium, and bone marrow.
Percentage of patients
(each)
1%

Primary site

Count

Endometrium
Esophagus
Intestine
Large Intestine
Lymph node
Parotid
Placenta
Rectum

13

39

2%

3%

4%

5%
10%
12%
24%

Supra Renal
Thyroid
Trachea+Esophagus
Unknown
Larynx
Bladder
Bone
Lymph
Kidney
Tongue
Brain
Buccal mucosa
Cervix
Lungs
Testis
Stomach
Plasma
Ovary
Breast
Blood

6

6

24

5
10
12
24

Table 10: Categorising count of each primary site of cancer

Figure 24: Legend and pie chart of all cancers
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6.4.2 Geographical Distribution of Cancer Patients Visiting Shirdi Sai Baba Cancer
Hospital and Research Centre
The n=100 patients recorded were found to hail from both coasts of Southern India but majority
of patients were from Karnataka.

Figure 25: Geographical distribution of primary sites of cancer in Southern India.
6.4.3 Region-wide distribution of cancers
Among n=100 patients, 47 (47%) were found to belong to Coastal Karnataka region, followed by
28 (28%) to South Karnataka, 17 (17%) to North Karnataka and 4 (4%) to Kerela. Few patients 2
(2%) hailed from Goa and Andhra Pradesh each.

Figure 26: Region-wide distribution of cancers
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6.4.4 Frequency of Distribution
The frequency of distribution of n=100 patients hailing from different parts of Southern India
were calculated. Most frequent visitors were patients from Coastal Karnataka i.e. with 0.47
frequency followed by 0.28 from South Karnataka, 0.17 from North Karnataka, 0.04 from
Kerala, 0.02 from Goa and 0.02 from Andhra Pradesh.

Figure 27: Frequency of distribution of cancer
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7. DISCUSSION
Age is one of the most important risk factors for most cancers. It has been shown that incidence
of cancers increases with age reaching higher levels during midlife. Studies show that majority
of cancers occurred in adults aged ≥65 years in 2009 (U.S statistics). (34) CDC statistics from the
US showed that that there is a relative increase in age associated cancer development (rate per
10000 people) and it peaks at ages 60-64. (35) These studies elucidate a similarity to our study of
age analysis with incidence of cancer which showed most patients in 51-60 years range.
The risk of at least one breast cancer history among subjects’ first‐degree relatives was relatively
high among pre‐ as well as post‐menopausal women. (36) Out of the 34 female patients who were
menopausal, it was found that 8 (23%) had ovarian and 8 (23%) had breast cancer, suggesting a
relationship between higher frequency of ovulation cycles and increased exposure to hormones
to play a significant role in cancer incidence. (37) Our study showed a 65% of menopausal patients
had cancer.
In our study, it was found that 5 (33.3%) of them had breast cancer and 7 (46%) had
gynecological cancers (ovarian, placental, and breast cancer). Studies suggest, having a first
degree relative with positive history of cancer is associated with relatively high cancer risk. (38)
11 cancer patients were found to have a drinking history (current/previous). 8 cancer patients
were found to have a smoking history (beedis/cigarettes) or areca nut consumption history.
Evidence shows that alcohol consumption can have an indirect link to the occurrence of cancers
like large bowel cancer and breast cancer in women but their associations have not yet been
proven unequivocally. It is strongly associated with liver cancer. (39) Synergistic effects between
alcohol and tobacco use has been observed and is found to show increased risks for cancers of
the upper digestive and respiratory tract. (40)
Increased amount of alcohol intake (i.e., more than four drinks per day) can lead to cancer
development at various sites. In contrast to this, lower amount of alcohol intake can lead to
moderate risk for various cancers. (39) Stronger associations have been found between smoking
and incidence of cancers like liver cancer, bladder cancer etc. Passive smoking also known as the
human carcinogen has been proven to cause 50000 deaths annually. Active smoking also
contributes to cancers of nasal passages sinuses, oral cavity, upper aerodigestive tract, pancreas,
gynaecological system, kidney, bladder, stomach, colorectum and acute myeloid leukaemia. (41)
13 patients were found to live in proximity to industries that could be a contributing factor to the
development of cancer. Types of industries include Steel, Nuclear power, Mechanical, Rice mill,
and Sugar etc. The duration of residence is also a significant factor. Some patients lived for as
much as 60 years near a steel factory. Pollution from industries has been currently associated
with the incidence of non-Hodgkin Lymphoma (NHL) due to chemical exposures. (42)
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Studies have shown that proximity to industries and presence of a confounding variable like
‘occupational exposure’ has significantly increased the risks for pleural, lung and bladder
cancers. (43)
In 2012, 75.2% of U.S. adults aged 45–54 years and 60.6% of those aged 55–64 years were
employed, making exposure to occupational carcinogens especially significant at this phase of
life. From our study, 15% of patients were exposed to chemicals. (34)
Treatment of pain associated with cancer is very vital to the aspects of palliative care in
oncology. Studies show that to 53% of patient’s oral administration of analgesics were given and
to 39% of patient’s parenteral administration of analgesics were given. Among the analgesics,
strong opioids were found to be efficacious in 68%, non-opioids were effective only in 10% and
in combination with weak opioids in 15 % of patients. Morphine was frequently used in 96 of
patients. (44) Though there are no evidences of paracetamol being the most used analgesic, it was
the most commonly used in our study.
In a study by Glaus et al, the frequency of nausea and vomiting in 243 cancer patients were
studied. It was observed that 42-52% of patients experienced the symptom and percentage of
38% experienced a late form of the symptom. (45) Research shows that if oncologists administer
anti-emetics like 5HT 3-receptor antagonists, NK receptor antagonists along with dexamethasone
for chemotherapy induced nausea and vomiting, it can be improved by 20% which is very similar
to our study since ondansetron was the most used anti-emetic. (46) (47)
For symptom relief, studies show that proton pump inhibitors (PPIs) are superior to both H2receptor antagonists (H2RAs) and pro-kinetics in achieving heartburn re-mission. Another study
showed that H2-receptor antagonists (H2RAs) is associated with less cancer risk compared to
PPIs. The most commonly used PPI in our study was pantoprazole. (48) (49)
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LIMITATIONS
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8. LIMITATIONS

1. After initial diagnosis, cancer registries were found to report the data after months.
Hence, there is a delay in the generation of reliable data by registries
2. Lack of professionally trained dedicated personnel in analyzing data
3. The inability to conduct survival analysis on the population data due to the requirement
of a large dataset.
4. Follow up and outcome analysis is time-consuming

5. Missing reports/lack of documentation if the patients get transferred from another
hospital
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9. CONCLUSION
Around 27 different types of primary sites of cancer were exhibited. With the most common
being “blood” (24), followed by “breast” (12) and “ovary” (10).
It is inferred that there is a diverse spatial distribution of the primary sites of cancers and their
geographical locations indicating the diversity of footfall in the hospital. Demographical factors
seem to play a significant role in the development of cancer.
All the above analyses reinforce the need for a registry for a hospital like Shirdi Sai Baba Cancer
Hospital and Research Centre to aid research and epidemiological assessments. It also aids
therapeutic decisions and points at drug utilization patterns useful for drug procurement.
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10. FUTURE DIRECTIONS
1. Expansion of the workforce to cover all patients admitted prospectively and follow-up
accurately
2. Adoption to the population-based registry
3. Data availability and accessibility to HCPs via web-based module
4. The inclusion of quality of life assessment parameters, pharmacoeconomics, and
genomics in the CRF
5. Design and execution of disease-specific CRFs
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APPENDIX I: CTRI REGISTRATION NO. & IEC CERTIFICATE
CTRI REGISTRATION NUMBER: CTRI/2018/10/016139
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APPENDIX ll a: ADULT PIS (ENGLISH)
PARTICIPANT INFORMATION SHEET
Project title: Development and evaluation of a Cancer registry for Shirdi Sai Baba Cancer
Institute, Manipal
IEC No.: 510/2018
Sponsor Name: Language: English
Principal Investigator: Dr.Kanav Khera
Designation: Associate Professor-Senior scale.
Hospital: Shirdi Sai Baba Cancer Hospital and Research Centre.
Mobile number: +919036253592
Please read this form carefully. If you don't understand the language or any information in this
document, please discuss it with the doctor. Your participation in this study is voluntary, and
you can inquire about all details before giving your written consent to participate in this study.
1. Introduction to the research study:
You are invited to participate in this study because you have been diagnosed with cancer.
2. Purpose of the study:
The purpose of the study is to develop an epidemiological database, reduce the prevalence and incidence
of cancers thereby aiding cancer research on the whole.
3. Who can take part:
INCLUSION CRITERIA: patients diagnosed with cancer
EXCLUSION CRITERIA: Patients who refuse to participate
4. Information about the study (as a whole):

The information collected from the patients will be pooled into a database that will be used for
epidemiological purposes.
The approximate sample size is 600-700 and the study period is of 2 years.
5. What will happen to you (the individual participant) during the study:
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Please provide information as enquired by the clinical pharmacist/physician. Your identity will remain
confidential. The approximate time taken for the data collection would be 2 hours and the information
will be gathered from your medical record file as well as lab reports. The total duration of the study would
be 2 years, regardless of your duration/frequency of admission to the hospital.
6. Your (the individual participant) role/responsibility in the study:




Provide accurate information whenever asked.
Inform the doctor about any problem/side effects experienced during the treatment.
If you want to discontinue from the study, inform the physician with a week’s notice.

7. What are the risks?
The risk involved is minimal as only clinically significant data is being collected.
8. What are the potential benefits of participating in the study?
There is no direct benefit from participating in this study. If you take part in this study you may
help other patients with cancer by contributing to the knowledge bank.
9. What are the alternative treatments available:
This study does not involve or influence any treatment, hence this section is not applicable.
10. Cost of participating in the study:
No additional costs for being a part of the study.
11. Compensation for injury:
If a medical problem arises during this study as a direct result of the study procedure, the study doctor
will be responsible for making sure that proper medical care is provided to you.
12. Confidentiality of information
Information from the study records including your medical records, results of tests, study
results will be kept confidential and will be reviewed only by authorized personnel from the
sponsor or their representative, Ethics Committee or regulatory bodies. Information and results
from this study may be presented at meetings or published in journals without including your
name and personal identifications.
13. New information about the study:
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Any new information available during the course of the study will be informed to you if it has relevance to
your decision regarding continuing in the study. The results of your participation will be disclosed to you if
you indicate your desire for it.
14. Voluntary participation:
Your participation in this study is voluntary; you may decline to participate at any time and you
need give written reason for the same, and such withdrawal shall be without penalty and
without loss of benefits to which you are otherwise entitled.
If you withdraw from the study before data collection is completed, your data collected until
your indicated withdrawal will be used in the study report. The sponsor or the investigator may
stop the research or your participation in it at any time for some or other reason without your
permission.
15. Whom to contact in case of any questions:
If you experience adverse effects as a result of participating in this study, you may contact the Principal
Investigator ( Dr. Kanav Khera ) as detailed above.

If you have any questions about the informed consent process or your rights as a participant,
you may contact the Member Secretary of the Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee at Room 22, Ground floor, KMC Faculty Rooms, adjacent to KMC
Administrative Block, Kasturba Medical College, Manipal - 576104. Phone: 0820 29 33522.
Timings: 9: 00 AM to 5: 00 PM.
If you have any questions about this form or any study related issue, you may also contact the
following person.
Name: Dr. Girish Thunga
Address: Department of pharmacy practice, MCOPS, Manipal.
Telephone No: +919880151127
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APPENDIX II c : PIS PAEDIATRIC (ENGLISH)
PARTICIPANT INFORMATION SHEET
Project title: Development and evaluation of a Cancer registry for Shirdi Sai Baba Cancer
Institute, Manipal
IEC No.:
Sponsor Name:
Language: English
Principal Investigator: Dr.Kanav Khera
Designation: Associate professor-Senior scale.
Hospital: Shirdi Sai Baba Cancer Hospital and Research Centre.
Mobile number:+919036253592.
Please read this form carefully. If you don't understand the language or any information in this
document, please discuss it with the doctor. Your child's participation in this study is voluntary,
and you can inquire about all details before giving your written consent for your child's
participation in this study.
1. Introduction to the research study:
Your child is being invited to participate in this study because your child has been diagnosed
with cancer.
2. Purpose of the study:
The purpose of the study is to develop an epidemiological database, reduce the prevalence and incidence
of cancers thereby aiding cancer research on the whole.
3. Who can take part:
INCLUSION CRITERIA: Patients diagnosed with cancer
EXCLUSION CRITERIA: Patients who refuse to participate
4. Information about the study (as a whole):

The information collected from the patients will be pooled into a database that will be used for
epidemiological purposes. The approximate sample size is 600-700 and the study period is of 2 years.
5. What will happen to you (the individual participant) during the study:
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Please provide information as enquired by the clinical pharmacist/physician. Your child’s identity will
remain confidential. The approximate time taken for the data collection would be 2 hours and the
information will be gathered from your child’s medical record file as well as lab reports. The total
duration of the study would be 2 years, regardless of your child’s duration/frequency of admission to the
hospital.
6. Your (the individual participant) role/responsibility in the study:




Provide accurate information whenever asked.
Inform the doctor about any problem/side effects experienced during the treatment.
If you want to discontinue from the study, inform the physician with a week’s notice.

7. What are the risks?


The risk involved is minimal as clinically significant data is been collected.

8. What are the potential benefits of participating in the study?
There is no direct benefit to your child from participating in this study. If your child takes part in
this study your child may help other patients with cancer by contributing to the knowledge
bank.
9. What are the alternative treatments available:
This study does not involve or influence any treatment, hence this section is not applicable.
10. Cost of participating in the study:
No additional costs are involved in being a part of the study.
11. Compensation for injury:
If a medical problem arises during this study as a direct result of the study procedure, the study doctor
will be responsible for making sure that proper medical care is provided to your child.
12. Confidentiality of information
Information from the study records including your child’s medical records, results of tests, study
results will be kept confidential and will be reviewed only by authorized personnel from the
sponsor or their representative, Ethics Committee or regulatory bodies. Information and results
from this study may be presented at meetings or published in journals without including your
child’s name and personal identifications.
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13. New information about the study:
Any new information available during the course of the study will be informed to you if it has relevance to
your decision regarding continuing in the study. The results of your child's participation will be disclosed
to you if you indicate any desire for it.
14. Voluntary participation:
Your child’s participation in this study is voluntary; you may decline to participate at any time
and you need give written reason for the same, and such withdrawal shall be without penalty
and without loss of benefits to which you are otherwise entitled.
If you withdraw from the study before data collection is completed, your child's data collected
until your indicated withdrawal will be used in the study report. The Sponsor or the investigator
may stop the research or your child's participation in it at any time for some or other reason
without your permission.
15. Whom to contact in case of any questions:
If your child experiences any adverse effects as a result of participating in this study, you may contact the
Principal Investigator ( Dr. Kanav Khera ) as detailed above.

If you have any questions about the informed consent process or your rights as a participant,
you may contact the Member Secretary of the Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee at Room 22, Ground floor, KMC Faculty Rooms, adjacent to KMC
Administrative Block, Kasturba Medical College, Manipal - 576104. Phone: 0820 29 33522.
Timings: 9: 00 AM to 5: 00 PM.
If you have any questions about this form or any study related issue, you may also contact the
following person.
Name: Dr. Girish Thunga
Address: Department of pharmacy practice, MCOPS, Manipal.
Telephone No: +919880151127
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APPENDIX III a: ICF ADULT (ENGLISH)
Project title: DEVELOPMENT AND EVALUATION OF CANCER REGISTRY FOR SHIRDI SAI BABA CANCER
HOSPITAL AND RESEARCH CENTRE
I confirm that I have read the Participant Information Sheet for the above study and its
contents were explained and I have had the opportunity to ask questions and received
satisfactory answers.
I understand that my participation in the study is voluntary and that I have the right to
withdraw at any time by giving a written reason, without my medical care or legal rights
being affected.
I agree to take part in the above study. I confirm that I have received a copy of the
Participant Information Sheet along with this signed and dated informed consent form.
Name of the Research Participant:
Age of the Research Participant:
Address of the Research Participant:
Occupation:
Annual Income of the Participant:
Name & address of the nominee(s) and his relation to the Participant:
_________________________________________________________________________

__________________________
Signature of the research subject

_________
Date

__________________________
Name & Signature of the witness

_________
Date

_______________________________________________
Name & Signature of the person explaining the consent

_________
Date
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APPENDIX III c: ICF PAEDIATRIC (ENGLISH)
Project title: DEVELOPMENT AND EVALUATION OF A CANCER REGISTRY FOR SHIRDI SAI BABA CANCER
HOSPITAL AND RESEARCH CENTER
I confirm that I have read the Participant Information Sheet for the above study and its
contents were explained and I have had the opportunity to ask questions and received
satisfactory answers.
I understand that my child's participation in the study is voluntary and that my child has the
right to withdraw at any time by giving a written reason, without my child's medical care or
legal rights being affected.
I agree to my child taking part in the above study. I confirm that I have received a copy of the
Participant Information Sheet along with this signed and dated informed consent form.
Name of the Research Participant:
Age of the Research Participant:
Address of the Research Participant:
_________________________________________
Name and signature of the mother /
guardian of the research subject

_________
Date

_________________________________________
Name & Signature of the participant child
for assent (if aged from 7 years to 18 years)

_________
Date

__________________________
Name & Signature of the witness

_________
Date

___________________________________________
Name & Signature of the person explaining the consent

_________
Date
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APPENDIX IV a: ADULT CRF
MANIPAL CANCER REGISTRY FORM
Accreditation No:
REPORTING PHYSICIAN INFORMATION
Name Of Physician:
Highest Qualification:
MCI Registration No:
Mobile Number:
DEMOGRAPHIC PARAMETERS OF THE PATIENT
(TO BE FILLED BY CLINICAL PHARMACIST)
Date Of Birth:
Age:
Gender:

☐☐/☐☐/☐☐☐☐
HOSPITAL NO:

☐Male ☐Female ☐Other
MARITAL STATUS: ☐married
☐unmarried

CASE REGISTERED AT:

☐Out-Patient (OP)
HEIGHT: ☐☐☐Cm

☐ In-Patient (IP)
WEIGHT: ☐☐☐Kg BMI:

☐☐☐Kg/m

2

MOTHER TONGUE:

☐Kannada ☐Malayalam ☐Tulu ☐Konkani ☐Others(Specify)____________
NAME OF RELATIVE/ACCOMPANYING PERSON:

☐Father ☐Mother ☐Son ☐Daughter ☐Spouse ☐Others: ___________
EDUCATION: ☐Illiterate ☐Literate, if Yes then ☐School going

☐Graduate
☐ Postgraduate ☐ NA
(For Children)
MEDICAL HISTORY (TO BE FILLED BY CLINICAL PHARMACIST)
ARE YOU PREGNANT?

☐Yes ☐No ☐NA

MENSTRUAL STATUS: ☐ Active ☐ Menopause ☐NA
ANY PREVIOUS BLOOD DISORDER OR INFECTIONS IN BLOOD?

☐Yes ☐No

If Yes, Specify (Year and relevant details):
___________________________
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HAVE YOU SUFFERED FROM ANY OTHER DISEASES?
If Yes, Specify: ________________

☐Yes ☐No

HISTORY OF CANCER: ☐ Yes ☐ No If Yes, Specify:____________
FAMILY HISTORY OF CANCER: ☐ Yes ☐ No If Yes,
Specify:____________
SOCIAL HISTORY
ALCOHOLIC: ☐ Yes ☐ No ☐NA
TYPE OF
☐Beer
ALCOHOL:
HOW OFTEN:
☐1- ☐ 1
☐ 2-4
3
Time/ Times/
Tim week week
es/
mon
th
HOW MUCH:
☐330 ml Bottle
☐500 ml Bottle

☐Wine
☐
5-6
Tim
es/
wee
k

☐1
Tim
e/
day

☐Hard
Liquor
☐2-3 ☐4-5 ☐6+
Time Times Times
s/
/day
/day
day

☐ Glasses

☐30 ml ☐60
ml
☐90 ml

SMOKING HISTORY:

☐Never Smoked

☐Former Smoker ☐Quit (If Yes, Since How Long:_______)

CURRENT TOBACCO USE:
☐Cigar/Pipe ☐Chew/Snuff ☐Cigarette
☐Beedi

NO. OF CIGARETTE(S)/DAY:
PACKS YEAR: (No. Of
Cigarette/Day )
X
(Total
Years Of Smoking)/20 =

OCCUPATION: ☐Employed;
Specify_________ ☐Unemployed ☐NA

FINANCIAL INCOME:
☐<1LAKH
☐1-5LAKH ☐>5LAKH

RESIDENCE NEAR INDUSTRIAL
AREA: ☐YES ☐NO

DURATION OF RESIDENCE IF
YES:
______YEARS/ MONTHS
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DURING WORK WERE YOU EXPOSED TO?
☐PESTICIDES ☐CHEMICAL ☐ RADIATION ☐ ROOFING CHEMICALS
(EG: TAR, SOOT) ☐ASBESTOS ☐COAL ☐PETROCHEMICALS
☐RUBBER
DETAILS IF ANY:

DIAGNOSTIC PARAMETERS (TO BE FILLED BY CLINICIAN)
DATE OF INITIAL DIAGNOSIS:
PRIMARY SITE:
SECONDARY
SITE:
☐☐/☐☐/☐☐☐☐
DIAGNOSTIC STATUS AT REGISTRATION:

☐Not Registered
☐Suspected

☐Microscopically Confirmed ☐Unknown
☐Unequivocal Clinical Diagnosis

DIAGNOSTIC CONFIRMATION:

☐Histology
☐Cytology
☐Micro-Confirmed
☐Direct Visualization
☐Clinical Diagnosis Only ☐Radiography
☐Lab Test/Marker Study ☐Unknown
PAIRED ORGAN/LATERALITY:

☐ Not App ☐Right ☐Left ☐Both ☐Side Not Specified ☐ Unknown
NAME OF CANCER:________
TREATMENT PARAMETERS (TO BE FILLED BY CLINICIAN)
STAGE OF DISEASE AT DIAGNOSIS:

☐In Situ

☐Regional, Direct

Extension

☐Regional, Direct Extension &Lymph Node
☐Regional,Lymph Node
☐Unstaged

☐Distant, Local
☐ Regional,Nos
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TYPE: ☐Acute ☐Chronic

TUMOR GRADE:___________

STAGING SYSTEM FOLLOWED: ☐TNM ☐FIGO ☐ANN HARBOR
☐OTHERS:_______
cTNM STAGING: T___ N___M______
pTNM staging: _______
TREATMENT GIVEN IN ANY OTHER
HOSPITAL:

☐Yes

☐No

SPECIFY TREATMENT:

☐Chemotherapy
☐Radiotherapy
☐Surgery
☐Others

INTENTION TO TREAT AT RI:

☐Curative/Radical ☐ Palliative ☐No Treatment
FIRST COURSE OF TREATMENT:

☐None

☐Patient-Refused Treatment

☐DIAGNOSTIC

PROCEDURE Only

☐Palliative Only
☐Excisional Biopsy
☐Cryosurgery
☐Surgery, Nos
☐Chemotherapy
☐Hormone Therapy
☐Others(Specify): ____
CYCLES COMPLETED:

1 Line Drug
st

☐Laser Surgery
☐Radiation
☐Immunotherapy
ANY ADVERSE
REACTION BEFORE OR
AFTER:

DRUG THERAPY
2 Line Drug
nd

3 Line Drug
rd

78

DATE OF THERAPY INITIATED:

DATE OF COMPLETION OF
TREATMENT:

☐☐/☐☐/☐☐☐☐

☐☐/☐☐/☐☐☐☐

CURRENT THERAPY:

OUTCOME
TREATMENT ADVISED BUT NOT RECEIVED ☐Yes ☐No
REASONS FOR NON-TREATMENT:

☐DECLINED TREAtment

☐Advised To Take Planned Treatment

Outside Ri

☐Death During Treatment
☐Death Before Treatment
☐Discontinued Because Of Inability To Tolerate During TreatmenT
☐ Unknown
DISEASE STATUS AT FIRST FOLLOW-UP OR AT 6 MONTHS WHICH
IS EARLIER:

☐NO EVIDENCE OF DISEASE (NEd)

☐Ned But Second Primary

Present

☐Ned But Non-Malignant Disease Present
Disease ☐Cancer In Progression

☐ Cancer In Regression/Residual
☐Too

Advanced/Cachexia

☐Patient Dead

☐Unknown

DATE OF LAST CONTACT:

DATE OF DEATH:

☐☐/☐☐/☐☐☐☐

☐☐/☐☐/☐☐☐☐
79

CAUSE OF DEATH: ____________
SOURCE OF INFORMATION ON ABOVE ITEMS:

☐Personal Interview And Abstraction Of Records

☐Abstraction Of Records

Only

☐Through Record Linkage
☐Others(Specify)________
☐Unknown
DATE: ☐☐/☐☐/☐☐☐☐
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MANIPAL CANCER REGISTRY FORM
Accreditation No:
REPORTING PHYSICIAN INFORMATION
Name Of Physician:
Highest Qualification:
MCI Registration No:
Mobile Number:
DEMOGRAPHIC PARAMETERS OF THE PATIENT
(TO BE FILLED BY CLINICAL PHARMACIST)
Date Of Birth:
Age:
Gender:

☐☐/☐☐/☐☐☐☐

☐Male ☐Female ☐Other

HOSPITAL NO:
CASE REGISTERED AT:

☐Out-Patient (OP)
HEIGHT: ☐☐☐Cm

☐ In-Patient (IP)
WEIGHT:

☐☐☐Kg

BMI: ☐☐☐Kg/m

2

MOTHER TONGUE:

☐Kannada ☐Malayalam ☐Tulu ☐Konkani ☐Others(Specify)____________
NAME OF RELATIVE/ACCOMPANYING PERSON:

☐Father ☐Mother ☐Son ☐Daughter ☐Spouse ☐Others: ___________
EDUCATION: ☐Illiterate ☐Literate, if Yes then ☐School going
MEDICAL HISTORY (TO BE FILLED BY CLINICAL PHARMACIST)
ISSUES DURING PREGNANCY?
YES,SPECIFY______

☐Yes ☐No ;IF

DEVELOPMENTAL HISTORY: ☐Appropriate

☐NA

BIRTH HISTORY: ☐NORMAL ☐LTCS
HAVE YOU SUFFERED FROM ANY OTHER DISEASES?
Yes, Specify: ________________

☐Yes ☐No

If

81

FAMILY HISTORY OF CANCER: ☐ Yes ☐ No If Yes,
Specify:____________
SOCIAL HISTORY OF MOTHER
ALCOHOLIC: ☐ Yes ☐ No ☐NA;
if yes,how much and how often?:_____________
SMOKING HISTORY: ☐ ACTIVE EXPOSURE ☐ PASSIVE EXPOSURE
If yes, details:_______
OCCUPATION(parents): ☐Employed; FINANCIAL INCOME: ☐<1LAKH
Specify_________ ☐Unemployed ☐NA ☐1-5LAKH ☐>5LAKH
RESIDENCE NEAR INDUSTRIAL
AREA: ☐YES ☐NO

DURATION OF RESIDENCE IF
YES:
______YEARS/ MONTHS

DURING WORK WERE YOU EXPOSED TO?
☐Pesticides ☐Chemicals ☐ Radiation ☐ Roofing Chemicals (Eg: Tar, Soot)
☐asbestos ☐coal ☐petrochemicals ☐rubber
DIAGNOSTIC PARAMETERS (TO BE FILLED BY CLINICIAN)
DATE OF INITIAL
DIAGNOSIS:

PRIMARY
SITE:

SECONDARY SITE:

☐☐/☐☐/☐☐☐☐
DIAGNOSTIC STATUS AT REGISTRATION:

☐Not Registered
☐Suspected

☐Microscopically Confirmed ☐Unknown
☐Unequivocal Clinical Diagnosis

DIAGNOSTIC CONFIRMATION:

☐Histology
☐Cytology
☐Micro-Confirmed
☐Direct Visualization
☐Clinical Diagnosis Only ☐Radiography
☐Lab Test/Marker Study ☐Unknown
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PAIRED ORGAN/LATERALITY:

☐ Not App ☐Right ☐Left ☐Both ☐Side Not Specified ☐ Unknown
Name of cancer:__________

TREATMENT PARAMETERS (TO BE FILLED BY CLINICIAN)
STAGE OF DISEASE AT DIAGNOSIS:

☐In Situ

☐Regional, Direct

Extension

☐Regional, Direct Extension &Lymph Node
☐Distant, Local
☐Regional, Lymph Node
☐ Regional, Nos
☐Unstaged
TUMOR GRADE:__________
TYPE: ☐Acute ☐Chronic
STAGING SYSTEM FOLLOWED: ☐TNM ☐FIGO ☐ANN HARBOR
☐OTHERS:_______
cTNM STAGING: T___ N___M______
pTNM staging: _______
TREATMENT GIVEN IN ANY OTHER
HOSPITAL:

☐Yes

☐No

SPECIFY TREATMENT:

☐Chemotherapy ☐Radiotherapy
☐Surgery
☐Others

INTENTION TO TREAT AT RI:

☐Curative/Radical ☐ Palliative ☐No Treatment
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FIRST COURSE OF TREATMENT:

☐None

☐Patient-Refused Treatment

☐DIAGNOSTIC

PROCEDURE Only

☐Palliative Only
☐Excisional Biopsy
☐Cryosurgery
☐Surgery, Nos
☐Chemotherapy
☐Hormone Therapy
☐Others(Specify): ____

CYCLES COMPLETED:

1 Line Drug
st

☐Laser Surgery
☐Radiation
☐Immunotherapy

ANY ADVERSE REACTION
BEFORE OR AFTER:

DRUG THERAPY
2 Line Drug
nd

3 Line Drug
rd
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DATE OF THERAPY
INITIATED:

DATE OF COMPLETION OF
TREATMENT:

☐☐/☐☐/☐☐☐☐

☐☐/☐☐/☐☐☐☐

CURRENT THERAPY:

OUTCOME
TREATMENT ADVISED BUT NOT RECEIVED ☐Yes ☐No
REASONS FOR NON-TREATMENT:

☐Declined Treatment

☐Advised To Take Planned Treatment

Outside RI

☐Death During Treatment
☐Death Before Treatment
☐Discontinued Because Of Inability To Tolerate During Treatment
☐ Unknown
DISEASE STATUS AT FIRST FOLLOW-UP OR AT 6 MONTHS WHICH
IS EARLIER:

☐No Evidence of Disease (NED)
☐Ned But Second Primary Present
☐Ned But Non-Malignant Disease Present ☐ Cancer In Regression/Residual
Disease ☐Cancer In Progression
☐Too Advanced/Cachexia
☐Patient Dead
☐Unknown
DATE OF LAST CONTACT:

DATE OF DEATH:

☐☐/☐☐/☐☐☐☐

☐☐/☐☐/☐☐☐☐
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CAUSE OF DEATH: ____________
SOURCE OF INFORMATION ON ABOVE ITEMS:

☐Personal Interview And Abstraction Of Records

☐Abstraction Of Records

Only

☐Through Record Linkage
☐Others(Specify)________
☐Unknown
DATE: ☐☐/☐☐/☐☐☐☐
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Development and Evaluation of a Cancer Registry for Shirdi Sai Baba Hospital
And Research Centre.
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